Clinuvel (ASX:CUV) share price falls despite positive update

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is tumbling in early morning trade despite releasing an update to market.

| More on:
laboratory microscope

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Clinuvel Pharmaceuticals Limited (ASX: CUV) share price is tumbling in early morning trade. This comes despite releasing an update to the market. At the time of writing, the biopharmaceutical company's shares are swapping hands for $27.99, down 2.3%.

What did Clinuvel announce?

The Clinuvel share price is being weighed down by investors despite the company's positive announcement.

According to this morning's release, Clinuvel advised that it has now expanded its DNA repair program. The clinical trials will now evaluate afamelanotide in skin cells which have been damaged by ultraviolet (UV) and sun exposure. Patients suffering from rare diseases such as XP-V and XP-C will be included in the study.

Following an agreement by clinical and academic experts, Clinuvel will seek to evaluate the safety and efficacy of afamelanotide.

The company explained how UV radiation damages skin cells, causing defects of the DNA helix. It noted that if left unrepaired, chemical changes to DNA could replicate, thus leading to irreversible damage (photoaging). Continued exposure could also progress to skin cancer, including melanoma.

XP patients in particular have genetic defects that contain impaired DNA repair processes. Thus, leading to an extreme risk of skin cancer. This is unlike most individuals who are able to protect themselves for UV damage and repair cellular DNA.

Afamelanotide is an active ingredient in SCENESSE. Moreover, it improves the function of skin cells that have been damaged. Clinuvel hopes that conducting trials with afamelanotide will produce the first positive results sometime this year.

Management commentary

Clinuvel chief scientific officer Dr. Dennis Wright commented:

XP patients are at extreme risk of skin cancer – up to 10,000 times that of the general population – due to their inability to repair damage caused by UV and sunlight, known as photodamage.

Afamelanotide has been shown to protect skin from UV and light, and repair photodamage. We are now working to confirm this concept in clinical trials with both XP patients and healthy volunteers.

About the Clinuvel share price

The Clinuvel share price has gained over 60% since this time last year. Currently, the share price is up 25% year-to-date. It's worth noting that the company's shares reached a 52-week high of $28.80 earlier this month.

Based on valuation grounds, Clinuvel commands a market capitalisation of around $1.38 billion, with 49.4 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Person handing out $50 notes, symbolising ex-dividend date.
Broker Notes

Where to invest $20,000 into ASX 200 shares

Brokers think these shares could be top picks for Aussie investors.

Read more »

The words short selling in red against a black background
Share Market News

These are the 10 most shorted ASX shares

Let's see which shares short sellers are targeting this week.

Read more »

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A female financial services professional with a manicured black afro hairstyle turns an ipad screen to show a client across the table a set of ASX shares figures in graph format.
Share Market News

Record CBA share price and blockbuster merger push ASX 200 financials sector to the top

ASX financial stocks led the 11 market sectors last week with a 1.95% gain.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Market News

CBA Shares in focus: How Australia's most valuable company is using AI to compete

Could AI initiatives drive CBA shares higher?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

asx share price represented by cartoon letters spelling the word FOMO
Share Market News

What did Macquarie's "FOMO Meter" reveal about the stock market in May?

Is the market getting frothy or is there still room to climb?

Read more »

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »